Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

NCT01100242 is registered in ClinicalTrials.gov with New Mexico Cancer Research Alliance as lead sponsor.

NCT NCT01100242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01100242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Lead sponsor
New Mexico Cancer Research Alliance
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2010
Completion date
February 28, 2015
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma